Correction: Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes

Related Posts

• Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis

  Background Checkpoint inhibitor pneumonitis (CIP) that does not respond to corticosteroids is termed steroid-refractory CIP.…

• Correction: Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity

• 1263 Characterizing steroid-refractory immunotherapy toxicities and effect of second-line immunosuppression on clinical outcomes

  Background Immune-related adverse events (irAEs) are major factors limiting optimal application of immune checkpoint inhibitors…